[go: up one dir, main page]

PL2016198T3 - Sposób przewidywania ryzyka działań niepożądanych leku poprzez określanie HLA-B 1502 - Google Patents

Sposób przewidywania ryzyka działań niepożądanych leku poprzez określanie HLA-B 1502

Info

Publication number
PL2016198T3
PL2016198T3 PL07797432T PL07797432T PL2016198T3 PL 2016198 T3 PL2016198 T3 PL 2016198T3 PL 07797432 T PL07797432 T PL 07797432T PL 07797432 T PL07797432 T PL 07797432T PL 2016198 T3 PL2016198 T3 PL 2016198T3
Authority
PL
Poland
Prior art keywords
hla
predicting
risk
determination
adverse drug
Prior art date
Application number
PL07797432T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Shuen-Lu Hung
Chih-Lung Shen
Chi-Feng Chang
Hsin-Yu Lin
Wei-Hsuan Chen
Original Assignee
Academia Sinica
Pharmigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2016198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica, Pharmigene Inc filed Critical Academia Sinica
Publication of PL2016198T3 publication Critical patent/PL2016198T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL07797432T 2006-05-11 2007-05-11 Sposób przewidywania ryzyka działań niepożądanych leku poprzez określanie HLA-B 1502 PL2016198T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
PCT/US2007/068782 WO2007134235A2 (en) 2006-05-11 2007-05-11 Hla alleles associated with adverse drug reactions and methods for detecting such
EP07797432.7A EP2016198B1 (en) 2006-05-11 2007-05-11 Method for predicting a risk of adverse drug reactions by determination of hla-b 1502

Publications (1)

Publication Number Publication Date
PL2016198T3 true PL2016198T3 (pl) 2013-12-31

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07797432T PL2016198T3 (pl) 2006-05-11 2007-05-11 Sposób przewidywania ryzyka działań niepożądanych leku poprzez określanie HLA-B 1502

Country Status (17)

Country Link
US (2) US7943309B2 (pl)
EP (1) EP2016198B1 (pl)
JP (1) JP2009536828A (pl)
KR (1) KR101450348B1 (pl)
CN (1) CN101454462A (pl)
AU (1) AU2007249225B2 (pl)
BR (1) BRPI0710436A8 (pl)
CA (1) CA2651954C (pl)
DK (1) DK2016198T3 (pl)
ES (1) ES2422735T3 (pl)
IL (1) IL194900A (pl)
MY (1) MY150648A (pl)
NZ (2) NZ572259A (pl)
PL (1) PL2016198T3 (pl)
PT (1) PT2016198E (pl)
TW (1) TWI335937B (pl)
WO (1) WO2007134235A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
WO2011130152A2 (en) * 2010-04-12 2011-10-20 Academia Sinica Method for identifying hla complexes associated with adverse drug reactions
JP5959634B2 (ja) * 2011-06-23 2016-08-02 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン フェニトインによって誘発される薬の副作用のリスク評価
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
WO2015041603A1 (en) * 2013-09-17 2015-03-26 Agency For Science, Technology And Research Method for detection of a genetic variant
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781B (zh) * 2014-09-26 2017-04-19 陕西佰美基因股份有限公司 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
JP7334263B2 (ja) * 2019-05-06 2023-08-28 チャン グァン メモリアル ホスピタル,リンコウ 疾患修飾性抗リウマチ薬によって誘発される重度の皮膚副作用を発症するリスクを評価するための方法、その検出キットおよびその使用
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
CN113308532A (zh) * 2021-05-28 2021-08-27 上海康黎诊断技术有限公司 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒,以及方法
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Hla-b*5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
JP4031028B2 (ja) * 1993-03-18 2008-01-09 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 特異的プライマー及びプローブセットを使用するhla−bタイピングの方法
US5550039A (en) 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2514649A1 (en) * 2003-02-17 2004-08-26 Novartis Ag Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
CA2651954C (en) 2014-02-25
WO2007134235A3 (en) 2008-01-17
JP2009536828A (ja) 2009-10-22
US8142999B2 (en) 2012-03-27
IL194900A (en) 2013-02-28
NZ597628A (en) 2013-07-26
CA2651954A1 (en) 2007-11-22
AU2007249225A1 (en) 2007-11-22
BRPI0710436A2 (pt) 2012-10-09
NZ572259A (en) 2012-03-30
EP2016198A4 (en) 2010-07-21
PT2016198E (pt) 2013-07-29
EP2016198A2 (en) 2009-01-21
CN101454462A (zh) 2009-06-10
BRPI0710436A8 (pt) 2018-06-26
US20080145846A1 (en) 2008-06-19
TWI335937B (en) 2011-01-11
MY150648A (en) 2014-02-14
WO2007134235A2 (en) 2007-11-22
AU2007249225B2 (en) 2013-06-27
TW200844238A (en) 2008-11-16
US7943309B2 (en) 2011-05-17
KR20090031671A (ko) 2009-03-27
ES2422735T3 (es) 2013-09-13
IL194900A0 (en) 2009-08-03
DK2016198T3 (en) 2013-07-15
EP2016198B1 (en) 2013-05-01
US20110212439A1 (en) 2011-09-01
KR101450348B1 (ko) 2014-10-14

Similar Documents

Publication Publication Date Title
PL2016198T3 (pl) Sposób przewidywania ryzyka działań niepożądanych leku poprzez określanie HLA-B 1502
IL179344A (en) Mobile Platform Tracking Method
EP2053961A4 (en) METHOD FOR DISPENSING A MEDICAMENT
SI2051996T1 (sl) Postopek za inženiring T-celičnih receptorjev
IL187470A0 (en) Device for quantitative analysis of a metabolite profile
EP2027253A4 (en) SUBSTATES FOR EFFECTING ANALYSIS REACTIONS
ZA200801392B (en) A method for evaluation of a gemstone
IL196624A0 (en) Method for identifying novel genes
PL2010717T3 (pl) Sposób obudowy ścian wykopów
ZA200704159B (en) Method for analysis of pellet-cladding interaction
GB2442343B (en) Method for detecting small oligonucleotides
EP1806393A4 (en) MICROREACTOR FOR GENETIC TEST
EP2087069A4 (en) IMPROVED FLUIDIZED COATING PROCESS
IL181971A0 (en) Computer installation for establishing a diagnosis
EP2180434A4 (en) ELECTRONIC SYSTEM FOR EMULATING THE CHAIN OF THE STRUCTURE OF DNA FROM A CHROMOSOME
ZA200810014B (en) Method for processing images of a simulator
IL188695A0 (en) Method for evaluating drug candidates
EP1939623A4 (en) METHOD FOR ULTRA-RAPID MEASUREMENT OF BIOMOLECULAR REACTION
EP2094862A4 (en) METHOD FOR PREDICTING THE RESPONSE TO THERAPY
GB2441349B (en) Method for sculpting
GB0604660D0 (en) Assay for phospholipidosis
IL194459A0 (en) A method for assaying antigens
GB0418529D0 (en) Method for analysing
GB2456690B (en) A method for quantitative detection of diabetes related immunological markers
EP2011001A4 (en) METHOD FOR DETERMINING THE MOST PROBABLE K LOCATION